Zivo Bioscience Inc (ZIVO) 0.0748 $ZIVO
Zivo Bioscience, Inc. Issues CEO Report for Q4 2015 and Q1 2016
GlobeNewswire - Mon Apr 18, 1:07PM CDT
In the nine months since the last shareholder meeting in late June of 2015, Zivo Bioscience (OTCQB:ZIVO) has continued to focus almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof, while developing the business case and production scale-up to cultivate and productize that algal biomass.
ZIVO Bioscience Makes Director Change, Invites Banking Veteran to Join Board of Directors
GlobeNewswire - Tue Mar 15, 9:47AM CDT
ZIVO Bioscience, Inc. (OTCQB:ZIVO), announced today that it has accepted the resignation of director Mr. Thomas Cox and invited Mr. Robert Rondeau to join the board of directors and serve in this capacity until his successor is appointed and qualified, or until his term expires.
Zivo Bioscience Moves Forward With Planned Pilot Production and Validation Studies Upon Q1 2016 $1M Funding Advance From Lead Investor
GlobeNewswire - Thu Mar 03, 10:04AM CST
Zivo Bioscience, Inc. (OTCQB:ZIVO) announced today that to date it has received $1 million in Q1 2016 funding advances from lead investor and primary lender HEP Investments, LLC, which allows the Company to immediately move forward with various projects and studies focused on commercialization of its proprietary algal products.
ZIVO Bioscience Executes Debt Restructure/Extension With Primary Lender, Expands Credit Line
Marketwired - Tue Jan 19, 7:13AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announced today that it has executed a significant debt restructuring agreement with its primary lender, HEP Investments, LLC, that extends default provisions on matured debt by a minimum of 15 months from today's date. Simultaneously, the ZIVO board approved an expansion of the credit line to $12.5 million under terms similar to those announced in January of 2015, most notably where the primary lender agreed to convert debt to ZIVO common stock at market prices on the date loans were originated, with no discounts upon conversion. Further, the primary lender agreed to an orderly conversion of outstanding debt to equity over time.
Zivo Bioscience Subsidiary, WellMetris LLC, Concludes Production Run of Human Wellness Testing Assays, Begins Validation
Marketwired - Mon Dec 21, 7:41AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announces today that its wholly-owned subsidiary, WellMetris LLC, has successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.
ZIVO Bioscience Opens WellMetris Assay Development Lab at Notre Dame Innovation Center
Marketwired - Wed Sep 09, 9:16AM CDT
ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced today that it has opened an assay development lab for its WellMetris subsidiary in South Bend, IN at the Innovation Center located near the Notre Dame University campus. The lab co-locates assay development and instrument engineering in order to streamline the product development process and focus on future development initiatives.
ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for June 23, 2015 in Detroit, Michigan
Marketwired - Wed Jun 17, 10:54AM CDT
ZIVO Bioscience, Inc., (OTCQB: ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Tuesday, June 23, 2015, beginning at 10:00AM EDT. The event will be held at the Westin Hotel located within the Detroit Metropolitan Airport (DTW) Midfield Terminal building, in the meeting room levels below the main atrium. The Company's management will share its progress on various research and product development efforts over the past year.
ZIVO Bioscience Announces Increase in Credit Facility From Primary Lender and Notice of Convertible Debt Conversion
Marketwired - Wed May 06, 7:30AM CDT
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announced today that it has received formal notice from HEP Investments, LLC increasing the amount of its credit facility to $8.5 million from $6 million. ZIVO board members unanimously approved a resolution to accept the increase and activate the lending provision. Further, HEP Investments advised ZIVO board of directors and management that it intends to incrementally convert a portion of its convertible debt into shares. This is part of an orderly process of conversion that HEP Investment intends to carry out over the next year.
ZIVO Bioscience Announces Amended Convertible Debt Structure and Continued Support From Primary Lender
Marketwired - Thu Jan 08, 12:31PM CST
Zivo Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., announced today that it has reached an accord with its primary lender, HEP Investments, LLC, to amend certain provisions in its convertible debt agreement, thereby limiting the dilutive effect previously created by conversion options.
ZIVO Bioscience Concludes Bovine Mastitis Pilot Study With Promising Results in Combatting Mycoplasma Pathogen
Marketwired - Tue Jan 06, 7:02AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., announced today that preliminary results and analyses of its pilot bovine mastitis study were accepted and reviewed by the Company's science team. Dairy Experts, Inc., based in northern California, conducted the study on behalf of the Company over the course of spring/fall 2014. The Company is awaiting a final report from the principal investigator leading the study team in California.
ZIVO Bioscience and WellMetris Subsidiary Announce Pilot Program and Pending Order for Point of Care Wellness Test
Marketwired - Tue Dec 02, 10:24AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., and its WellMetris subsidiary announced today that Trion Solutions, Inc., a leading human resources company with over 1,000 clients, and 15,000 employees, has committed to a pilot program to evaluate the health and economic benefits offered by the Company's proprietary Wellness Profile testing platform. Five-hundred Trion employees will initially take the test, which measures several key areas of metabolic health, including lipid peroxidation, inflammation, hydration and nitrite/nitrate balance, among others.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Nov 11, 1:08PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature three companies on Fox Business nationwide on Tuesday, November 11 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg Europe on Sunday, November 16 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, November 16 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday November 16 at 3:30 p.m. HKT.
Zivo Bioscience, Inc. Issues CEO Report for Q4 2015 and Q1 2016
GlobeNewswire - Mon Apr 18, 1:07PM CDT
In the nine months since the last shareholder meeting in late June of 2015, Zivo Bioscience (OTCQB:ZIVO) has continued to focus almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof, while developing the business case and production scale-up to cultivate and productize that algal biomass.
ZIVO Bioscience Makes Director Change, Invites Banking Veteran to Join Board of Directors
GlobeNewswire - Tue Mar 15, 9:47AM CDT
ZIVO Bioscience, Inc. (OTCQB:ZIVO), announced today that it has accepted the resignation of director Mr. Thomas Cox and invited Mr. Robert Rondeau to join the board of directors and serve in this capacity until his successor is appointed and qualified, or until his term expires.
Zivo Bioscience Moves Forward With Planned Pilot Production and Validation Studies Upon Q1 2016 $1M Funding Advance From Lead Investor
GlobeNewswire - Thu Mar 03, 10:04AM CST
Zivo Bioscience, Inc. (OTCQB:ZIVO) announced today that to date it has received $1 million in Q1 2016 funding advances from lead investor and primary lender HEP Investments, LLC, which allows the Company to immediately move forward with various projects and studies focused on commercialization of its proprietary algal products.
ZIVO Bioscience Executes Debt Restructure/Extension With Primary Lender, Expands Credit Line
Marketwired - Tue Jan 19, 7:13AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announced today that it has executed a significant debt restructuring agreement with its primary lender, HEP Investments, LLC, that extends default provisions on matured debt by a minimum of 15 months from today's date. Simultaneously, the ZIVO board approved an expansion of the credit line to $12.5 million under terms similar to those announced in January of 2015, most notably where the primary lender agreed to convert debt to ZIVO common stock at market prices on the date loans were originated, with no discounts upon conversion. Further, the primary lender agreed to an orderly conversion of outstanding debt to equity over time.
Zivo Bioscience Subsidiary, WellMetris LLC, Concludes Production Run of Human Wellness Testing Assays, Begins Validation
Marketwired - Mon Dec 21, 7:41AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announces today that its wholly-owned subsidiary, WellMetris LLC, has successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.
ZIVO Bioscience Opens WellMetris Assay Development Lab at Notre Dame Innovation Center
Marketwired - Wed Sep 09, 9:16AM CDT
ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced today that it has opened an assay development lab for its WellMetris subsidiary in South Bend, IN at the Innovation Center located near the Notre Dame University campus. The lab co-locates assay development and instrument engineering in order to streamline the product development process and focus on future development initiatives.
ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for June 23, 2015 in Detroit, Michigan
Marketwired - Wed Jun 17, 10:54AM CDT
ZIVO Bioscience, Inc., (OTCQB: ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Tuesday, June 23, 2015, beginning at 10:00AM EDT. The event will be held at the Westin Hotel located within the Detroit Metropolitan Airport (DTW) Midfield Terminal building, in the meeting room levels below the main atrium. The Company's management will share its progress on various research and product development efforts over the past year.
ZIVO Bioscience Announces Increase in Credit Facility From Primary Lender and Notice of Convertible Debt Conversion
Marketwired - Wed May 06, 7:30AM CDT
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announced today that it has received formal notice from HEP Investments, LLC increasing the amount of its credit facility to $8.5 million from $6 million. ZIVO board members unanimously approved a resolution to accept the increase and activate the lending provision. Further, HEP Investments advised ZIVO board of directors and management that it intends to incrementally convert a portion of its convertible debt into shares. This is part of an orderly process of conversion that HEP Investment intends to carry out over the next year.
ZIVO Bioscience Announces Amended Convertible Debt Structure and Continued Support From Primary Lender
Marketwired - Thu Jan 08, 12:31PM CST
Zivo Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., announced today that it has reached an accord with its primary lender, HEP Investments, LLC, to amend certain provisions in its convertible debt agreement, thereby limiting the dilutive effect previously created by conversion options.
ZIVO Bioscience Concludes Bovine Mastitis Pilot Study With Promising Results in Combatting Mycoplasma Pathogen
Marketwired - Tue Jan 06, 7:02AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., announced today that preliminary results and analyses of its pilot bovine mastitis study were accepted and reviewed by the Company's science team. Dairy Experts, Inc., based in northern California, conducted the study on behalf of the Company over the course of spring/fall 2014. The Company is awaiting a final report from the principal investigator leading the study team in California.
ZIVO Bioscience and WellMetris Subsidiary Announce Pilot Program and Pending Order for Point of Care Wellness Test
Marketwired - Tue Dec 02, 10:24AM CST
ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., and its WellMetris subsidiary announced today that Trion Solutions, Inc., a leading human resources company with over 1,000 clients, and 15,000 employees, has committed to a pilot program to evaluate the health and economic benefits offered by the Company's proprietary Wellness Profile testing platform. Five-hundred Trion employees will initially take the test, which measures several key areas of metabolic health, including lipid peroxidation, inflammation, hydration and nitrite/nitrate balance, among others.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Nov 11, 1:08PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"TM) television program will feature three companies on Fox Business nationwide on Tuesday, November 11 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg Europe on Sunday, November 16 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, November 16 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday November 16 at 3:30 p.m. HKT. 
